Esparma Gmbh

Roehm Pharma Gmbh

Other

Merck Patent Gmbh

Wolfgang A Wohlrab

Reinhard Neubert

Christoph Huschka

Gerhard Fries

Dieter Koegst

Katrin Wellner

J&ouml;rg-Herman Ozegowski

Peter-J&uuml;rgen M&uuml;ller

Lothar Motitschke

Hansj&uuml;rgen Driller

Joachim B&uuml;nger

J&uuml;rgen Schneider

Birgit Draeger

Tino Galgon

Sabine Matschiner

Sybille Matschiner

The invention relates to an agent for treating skin diseases and/or functional disorders of the skin on the basis of different medicaments and/or auxiliary substances through promotion of penetration from topical formulations into the skin. According to the invention, the agent is composed of a hyaluronate lyase produced by microbial means and a medicament, preferably a hydrophilic medicament and/or auxiliary substances in different galenic formulations including colloidal carrier systems. The areas of application for the invention in human and veterinary medicament relate to the treatment, prophylaxis and/or metaphylaxis of skin diseases, functional disorders of the skin, the processes of skin ageing and dry skin conditions.

Hyaluronate lyase used for promoting penetration in topical agents

The invention relates to an agent for the treatment, prophylaxis and metaphylaxis of functional and structural disorders of the skin caused by external factors. The agent contains a hyaluronic acid partially digested with a microbiological hyaluronate lyase. The hyaluronic acid fragment mixture is incorporated in different galenic formulations to which other hydrophilic and/or lipophilic active substances and/or auxiliary substances can be added. Fields of application of the invention in human and veterinary medicine relate to the treatment and/or the prophylaxis of skin damage caused by environmental factors including UV, dry skin conditions and skin ageing.

Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis

The invention relates to galenic formulations which contain a) one or more compounds selected from biotin, its physiologically compatible salts, biotin esters and the steroisomeric forms of these compounds; and b) one or more compounds selected from urea and urea derivatives. The above formulations are suitable for use as topically administered formulations for the cosmetic and/or medical treatment of the skin, hair and/or nails.

Galenic formulation containing biotin

The invention relates to a pharmaceutical preparation in a make-up which is suited for external application and which contains a dithranol derivative as an active ingredient.

Pharmaceutical preparation containing dithranol

A method of producing betulinic acid from the bark of plane trees by fractional extraction with a solvent of medium polarity and subsequent recrystallization out of methanol.

Method of producing betulinic acid

A stable topical formulation with good active ingredient release characteristics, comprising at least one macrolide antibiotic which is lipophilized with at least one former of oppositely charged ions which is selected from the group consisting of alkyl sulfates, alkylsulfonates, and alkyl salicylates, RX, where R represents a linear and/or branched alkyl group with 6-32 C atoms, and X represents a sulfate, sulfonate, or salicylate group.

Stable topical formulations with good active ingredient release

The invention relates to a nail lacquer for treating onychomycosis, comprised of a film-forming agent, an antimycotically active substance, and urea, wherewith the antimycotically active substance and the urea are liberated from the lacquer when the lacquer is applied. A preferred formulation comprises cellulose derivative(s) as film former(s), clotrimazole as the antimycotic (present in the amount of 5-30 wt. % based on the weight of the non-volatile components), urea (present in the amount of 15-60 wt. % based on the weight of the non-volatile components), and dibutyl phthalate as a plasticizer, in a solvent mixture comprised of acetone and ethanol.

Growing community of inventors

Halle, Germany

Wolfgang A Wohlrab